Results to Date
Hemolysis and von Willebrand Factor (vWF) Testing
In vitro benchtop testing results concluded that Hemoglide causes negligible levels of hemolysis and allows vWF to remain intact.¹ A well-designed VAD would minimize hemolysis, which occurs when red blood cells carrying oxygen are destroyed. vWF is a glycoprotein that promotes platelet adhesion in order to maintain hemostasis.
Acute Ex Vivo Study
Ex vivo results concluded that there were no ACT abnormalities while the blood was being cycled through Hemoglide.¹ Activated Clotting Time (ACT) is a measurement of how quickly blood clots.
In Vitro Thrombosis Testing
In vitro benchtop results concluded that Hemoglide is highly thromboresistant.¹ Thrombosis is another name for a blood clot, and a VAD's thromboresistance measures its ability to resist blood clot formation.
-b8c5882.jpeg/:/cr=t:0%25,l:0%25,w:100%25,h:100%25/rs=w:1209,cg:true)
7-Day In Vivo Study
In vivo results concurred with initial findings about Hemoglide's thromboresistance while also concluding that kidney function was not negatively impacted as a result.¹ This test continued to test the thromboresistance of Hemoglide by placing it within a living sheep for 7 days. The sheep's kidneys were also monitored for functional decline.